Author: Veloxis Pharmaceuticals, Inc

Posted Date:

April 22, 2026

Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients

Veloxis Pharmaceuticals, Inc

April 22, 2026
Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology

Veloxis Pharmaceuticals, Inc

March 30, 2026